[ASAP] Superiority of the Triple-Acting 5-HT6R/5-HT3R Antagonist and MAO-B Reversible Inhibitor PZ-1922 over 5-HT6R Antagonist Intepirdine in Alleviation of Cognitive Deficits in Rats 🔗 Access full article via ACS Journal of Medicinal ChemistryShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
